文献速递白血病造血干细胞移植与细胞治疗

急性髓系白血病缓解后克隆性造血的克隆动态与临床意义

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia.
PubMed 文献 · Blood · 2021-01-01

该研究纳入164例诱导化疗后达完全缓解的AML患者,48%可检出缓解后克隆性造血(CH),其中91%可追踪患者长期持续存在;异基因干细胞移植可清除95%患者的缓解后CH。缓解后CH总体不影响复发风险、非复发死亡和动脉粥样硬化性心血管疾病发生率,但持续性TET2突变者长期中性粒细胞减少。

要点

  • AML缓解后CH常见(48%),且多数长期持续,对巩固和维持治疗抵抗。
  • 异基因干细胞移植可清除多数患者的缓解后CH(95%)。
  • 持续性TET2突变与长期中性粒细胞减少相关,但总体临床影响有限。

核心结论

  • 缓解后残留的克隆性造血干细胞通常对巩固和维持治疗抵抗,但保留维持正常造血的能力,对临床结局影响较小。
  • 不同突变类型的临床影响存在异质性,需更大规模研究解析基因特异性差异。

研究设计与样本

  • 研究纳入164例经诱导化疗后达到完全缓解的急性髓系白血病患者,分析缓解后克隆性造血的患病率、动态及临床意义。

主要发现

  • 79例(48%)患者检出缓解后克隆性造血。
  • 可追踪患者中91%的缓解后克隆性造血长期持续存在,尽管接受了多种巩固和维持治疗。
  • 21例接受异基因干细胞移植的患者中20例(95%)缓解后克隆性造血被清除。
  • 持续性TET2突变患者长期表现显著的中性粒细胞减少。
  • 缓解后克隆性造血对复发风险、非复发死亡和动脉粥样硬化性心血管疾病发生率影响较小,但不同突变临床影响异质。

临床怎么用

  • AML缓解后检出CH较常见,不应仅因此改变巩固或维持治疗策略。
  • 异基因干细胞移植可有效清除缓解后CH,但需结合移植适应证综合决策。
  • 对持续性TET2突变患者,应关注长期中性粒细胞减少并加强监测。

局限性

  • 研究样本量有限,需更大规模研究解析不同基因突变对临床结局的异质性影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although clonal hematopoiesis (CH) can precede the development of acute myeloid leukemia (AML), it can also persist after achieving remission. Long-term clonal dynamics and clinical implications of persistent CH are not well understood. Here, we studied the prevalence, dynamics, and clinical implications of postremission CH in 164 AML patients who attained complete remission after induction chemotherapies. Postremission CH was identified in 79 (48%) patients. Postremission CH persisted long term in 91% of the trackable patients despite treatment with various types of consolidation and maintenance therapies. Postremission CH was eradicated in 20 out of 21 (95%) patients who underwent allogeneic stem cell transplant. Although patients with postremission CH as a group had comparable hematopoiesis with those without it, patients with persistent TET2 mutations showed significant neutropenia long term. Postremission CH had little impact on relapse risk, nonrelapse mortality, and incidence of atherosclerotic cardiovascular disease, although the clinical impact of post-CR CH was heterogeneous among different mutations. These data suggest that although residual clonal hematopoietic stem cells are generally resistant to consolidation and maintenance therapies, they retain the ability to maintain normal hematopoiesis and have little impact on clinical outcomes. Larger study is needed to dissect the gene-specific heterogeneity.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Tanaka T, Morita K, Loghavi S, et al. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood. 2021. PMID: 34115096. doi:10.1182/blood.2020010483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。